Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pulling iclaprim out of the ashes

This article was originally published in Scrip

Executive Summary

Seven years ago, the antibiotic iclaprim looked dead in the water. Seven months ago, Motif Bio was barely a blip on the biotech radar. But seven years is a long time in the antibiotic space, and seven months is a long time in biotech. Things are looking very different for both iclaprim and Motif. Scrip met with CEO Graham Lumsden, formerly of Merck & Co, and chairman Richard Morgan, CEO of majority shareholder Amphion Innovations, to get the details.


Related Content

Motif Bio Poised For Filings As Iclaprim Succeeds Again In Phase III
Motif A Step Closer To Succeeding With Iclaprim After Phase III Success

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts